IGEM Therapeutics Shortlisted as a Finalist in the “Best Start-up Biotech Company” Category of the 2018 OBN Awards
In All, PortfolioLondon, 22 August 2018 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced that it has been shortlisted as a finalist in the 2018 OBN Awards in the “Best Start-up Biotech Company” category. The “Best Start-up…